Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
Abstract We retrospectively investigated the pharmacokinetics and exposure‐efficacy/safety relationships of single‐agent atezolizumab based on tissue tumor mutational burden (tTMB) status (high vs low [≥16 vs <16 mutations/megabase]) in a pan‐tumor population from seven clinical trials. Data sour...
Main Authors: | Colby S. Shemesh, Phyllis Chan, Fatema A. Legrand, David S. Shames, Meghna Das Thakur, Jane Shi, Lorna Bailey, Shweta Vadhavkar, Xian He, Wei Zhang, René Bruno |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-12-01
|
Series: | Pharmacology Research & Perspectives |
Subjects: | |
Online Access: | https://doi.org/10.1002/prp2.685 |
Similar Items
-
Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region
by: Colby S. Shemesh, et al.
Published: (2021-06-01) -
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
by: Colby S. Shemesh, et al.
Published: (2019-11-01) -
Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
by: Ali AL Zahrani, et al.
Published: (2021-03-01) -
Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer
by: Toshiyuki Sumi, et al.
Published: (2021-07-01) -
Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis
by: Tie Y, et al.
Published: (2019-02-01)